Resources
- sort by:
- Relevance
- Date
- Popularity
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- Abbott Labs' Secret Weapon: Layoffs
- Sometimes a company does everything right and no one notices: Abbott Labs just unveiled a stellar third quarter and investors shrugged, leaving its stock flat. The basics you already know: Profit up 51 percent to $1.08 billion, sales up 17.6 percent to $7.5 billion. But check out...
- Blog posts 2008-10-15
- Zacks.com Announces That Kelley Wright Highlights the Following Stocks: Abbott Labs and The Limited
- CHICAGO -- Kelley Wright, editor of the Investment Quality Trends newsletter, says short rates will eventually move lower again. Read about Abbott Labs (NYSE:ABT) and The Limited (NYSE:LTD). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from the October 17 Featured Expert column by Kelley Wright...
- Research articles 2005-10-20
- Abbott Labs: Perfect Stock for Trying Times?
- Paul Price submits: Abbott Labs (NYSE:ABT) April 12, 2009 $44.03 52-week range: $42.62 (April 7, 2009) - $60.78 (Sep. 29, 2008) Dividend: $0.40 quarterly = 3.63% current yield Abbott consists of four major divisions- Pharmaceuticals, Nutritional Products, Diagnostic Products and Vascular treatment products. ABT has an enviable record of earnings...
- External links 2009-04-13
- Starved of News, Press Speculates on Deals for Abbott, Pfizer and Wyeth
- New Year is a slow news period, which is why the business press filled up with next-to-useless corporate strategy stories about Abbott Labs, Wyeth and Pfizer. The one thing these stories all have in common? They're long on speculation and short on substance. Let's take them one at a time....
- Blog posts 2009-01-05
- Abbott's Q4 Earnings Contain Surprises as Company Reverses Course on Staff Cuts
- Abbott Labs reported its Q4 earnings today and the news was good: revenues up 10 percent to $7.9 billion; net income up 28 percent to $1.54 billion. The results came after a stellar Q3. But despite the good news, one analyst still doesn't quite trust Abbott. Citigroup's...
- Blog posts 2009-01-21
- Analyst face-off: Abbott Labs
- NEW YORK Fortune -- Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion. Over the past few years, investors have cheered on Abbott, a $26 billion health care...
- News items 2009-08-07
- With Buybacks, J&J, Abbott, and Pfizer All See the Same Thing: Cheap Stock
- Abbott Labs announced a $5 billion stock buyback plan Monday. Such plans are often used by companies seeking to prop up stock that’s down for a good reason, i.e. the company sucks. But in a market like this one, where everyone is down at bizarre lows, suddenly those buybacks look...
- Blog posts 2008-10-13
- Abbott CEO White Takes a Pay Cut
- Abbott Labs CEO Miles White took a pay cut last year. His total compensation was only $28.3 million, down from $33.3 million the year before, per a proxy filing at the SEC. The cut came despite the judgment by Abbott's board that White "exceeded" his strategic and...
- Blog posts 2009-03-18
- 7 Drug Companies Explain How They Dodged (or Didn't) the Credit Crisis
- Drug companies have been the eye of the storm in the recent liquidity crash. High profitability, high cashflow (and making products that people literally can't live without) have left them in a comfortable economic position compared to other consumer-oriented companies. Here’s a selection from recent earnings calls...
- Blog posts 2008-10-22
- EXACT Sciences' Key to Future Earnings
- Mike Havrilla submits: The stock research section of BioMedReports.com has been updated on 8/1/09 for my new report on EXACT Sciences (NASDAQ:EXAS), which provides a more comprehensive and global earnings model for the company's next-generation stool DNA sDNA screening test (V3) for colorectal cancer (CRC) since my previous article in...
- External links 2009-08-02
- The 10 Weirdest Drug Stories of the Month
- Another page has been torn off the calendar, and that means it's time to open up Big Pharma's vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug...
- Blog posts 2008-10-01
- UPDATED: Why Zetia Researchers' Silence on Ending of Niaspan Trial Is Unfair to Merck
- Dr. Allen Taylor, an ARBITER-6 HALT trial investigator, should probably avoid talking to Merck investors for the next few weeks lest he get punched in the nose. It was Allen and his colleagues' unexplained announcement that they had stopped an Abbott Labs-funded comparison of Merck's Zetia with Abbott's Niaspan that...
- Blog posts 2009-07-10
- Sanofi CEO Viehbacher Wants More Cuts; Drug Reps' Necks on the Block
- Sanofi-Aventis's Q4 earnings call tomorrow could set the stage for a dramatic few days at the company, according to Bloomberg, as CEO Chris Viehbacher told analysts and his staff that Sanofi needs to cut operating costs and possibly buy a small or midsize firm. Viehbacher wants to get $1.3 billion...
- Blog posts 2009-02-10
- Sohu.com: 220M Chinese Internet Users and Growing
- Michael Michaud submits: After scanning the stock charts this early Monday morning, I’ve come up with two stock picks. One is a short-sell and the other is a buy candidate. The short-sell I won’t write about this week, because the long candidate is much more exciting and a longer term...
- External links 2008-09-15
- TIP: The Best Fixed Income Investment, For Now
- Hao Jin submits: Warren Buffett said that the US economic situation is not as bad at World War II or the Great Depression, but it's still pretty severe. Common sense is that the current credit crisis must be solved before the stock market can be turned around. However,...
- External links 2009-01-19
- Vivus Beating Arena, Orexigen In Obesity Graveyard Race
- The race to produce a blockbuster anti-obesity pill -- a contest that no company has yet won -- got interesting this week with the news, via AP, that Arena Pharmaceuticals' data showed that its contender, lorcaserin, showed only 3.6 percent more effectiveness than a placebo. The FDA wants to see...
- Blog posts 2009-03-31
- Pharma Roundup: Profitability of Cancer Research Questioned, "Voluntary" Label Change Suggested by FDA, and More
- Is there money in cancer research? Also, "voluntary" label change came from FDA; Abbott Labs repurchasing $5 billion in stock. by John Maas
- Blog posts 2008-10-13
- ON HOLD - Earnings Stocks for Wednesday ABT AMR BSX GD JPM OXY.
- M2 PRESSWIRE-18 October 2006-Web Karma LLC: ON HOLD - Earnings Stocks for Wednesday ABT AMR BSX GD JPM OXYC1994-2006 M2 COMMUNICATIONS LTD RDATE:18102006 Abbott Labs (NYSE: ABT) is expected to report earnings before the open Wednesday with analysts looking for EPS...
- Research articles 2006-10-18
- Arena Lays Off 31% of Its Staff Following Obesity Trial Failure
- Arena Pharmaceuticals is to lay off 31 percent, or 130 employees, before June 22, the company told the SEC. Arena staffers -- whose future is dependent on an anti-obesity drug, lorcaserin -- may be forgiven for wondering how it has all gone wrong so quickly. In February, Arena CEO...
- Blog posts 2009-04-27
- << Previous
- page 1 of 2
- Next >>
Presented by American Express